HtrA1 is a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer

Vincenzo Catalano (1) , Pasquale Mellone (2) , Alfredo d'Avino (2) , Viji Shirdhar (3) , Mariapia Staccioli (1) , Francesco Graziano (1) , Paolo Giordani (1) , David Rossi (1) , Annamaria Baldelli (1) , Paolo Alessandroni (1) , Daniele Santini (4) , Laura Lorenzon (5) , Enrico Testa (6) , Silvia d'Emidio (1) , Michele de Nictolis (1) , Paolo Muretto (1) , Stefano Luzi Fedeli (1) , Alfonso Baldi (7)

1 Medical Oncology
2 Biochemistry
3 Experimental Medicine
4 Oncology
5 Surgery
6 Oncology
7 Biochemistry, Sect Pathology

Aims HtrA1 is a member of the HtrA (High-temperature-requirement) family of serine proteases. HtrA1 plays protective role in various malignancies due to its tumour suppressive properties. This study was performed to determine HtrA1 expression as a predictor of chemoresponse in patients with advanced gastric cancer. Methods and Results HtrA1 expression was determined by immunohistochemistry on specimens of primary gastric cancer from 80 patients treated consecutively with cisplatin-based combination chemotherapy. Response to chemotherapy was assessed according to RECIST criteria. Our population consisted of M/F 51/29; median age 64 years (range, 32-82). A complete or partial response was observed in 71.4% (95% CI, 54.7-88.2), 66.7% (95% CI, 47.8-85.5), and 28.6% (95 CI, 11.8-45.3) of tumours showing high, medium, and low HtrA1 expression, respectively. A statistically significant association between HtrA1 expression and the clinical response was observed (p = 0.002). The median overall survival for patients with high/medium expression was 17 months compared to 9.5 months for patients with low HtrA1 expression (p = 0.037). Conclusions Identification of HtrA1 in gastric cancer prior to chemotherapy indicates that levels of HtrA1 could be used to predict response to platinum-based combination therapies. Further assessment of HtrA1 expression is highly warranted in large, prospective studies. .

Mots clés: Medicine

Vincenzo Catalano, Pasquale Mellone, Alfredo d'Avino, Viji Shirdhar, Mariapia Staccioli, et al.. HtrA1 is a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer. Histopathology, 2011, 58 (5), pp.669. ⟨10.1111/j.1365-2559.2011.03818.x⟩. ⟨hal-00627935⟩